| answer text |
<p>The 2019 voluntary scheme for branded medicines pricing and access contains ambitions
to improve patients’ outcomes and the health gain from medicines spend by simplifying,
streamlining and improving access, pricing and uptake arrangements for cost-effective
medicines; and delivering faster adoption of the most clinically and cost-effective
medicines.</p><p>This will be supported by changes to the National Institute for Health
and Care Excellence’s value assessment of new products, availability of increased
commercial flexibility, and support for the National Health Service to increase uptake
where appropriate. Use of products, particularly those which provide greatest health
gain for patients, will be monitored and reviewed through this scheme. NHS England
is developing a cohesive commercial framework to support this.</p>
|
 |
